Pharmacological management of South Asians with type 2 diabetes: Consensus recommendations from the South Asian Health Foundation

Wasim Hanif; Sarah Ali; Srikanth Bellary; Vinod Patel; Azhar Farooqi; Muhammad Ali Karamat; Mujahid Saeed; Sobha Sivaprasad; Kiran Patel; Kamlesh Khunti

doi:10.1111/dme.14497

Pharmacological management of South Asians with type 2 diabetes: Consensus recommendations from the South Asian Health Foundation

Wasim Hanif
, Sarah Ali
, Srikanth Bellary
, Vinod Patel
, Azhar Farooqi
, Muhammad Ali Karamat
, Mujahid Saeed
, Sobha Sivaprasad
, Kiran Patel
, Kamlesh Khunti

Aston University

Diabetes & Endocrinology Consultant Physician CSL Diabetes, University Hospitals of Birmingham, Trustee, South Asian Health Foundation UK
Consultant in Diabetes and Endocrinology Royal Free London NHS Foundation Trust, Diabetes Working Group Member, South Asian Health Foundation UK
Diabetes and Clinical Skills Warwick Medical School University of Warwick, Trustee, South Asian Health Foundation Warwick UK
East Leicester Medical Practice. Chair Leicester City CCG Clinical Director BME Centre for Health ARC East Midlands Leicester UK
Consultant Physician and Honorary Lecturer Diabetes and Endocrinology, ITF Clinical Tutor UHB TPD Diabetes and Endocrinology Health Education Birmingham UK
Regional Neuromuscular Clinic, Queen Elizabeth Hospital; University Hospitals of Birmingham; Birmingham UK
NIHR Moorfields Biomedical Research Centre and UCL Institute of Ophthalmology 162, City Road London UK
Consultant Cardiologist University Hospitals Coventry & Warwickshire NHS Trust, Honorary Chair, Warwick Medical School, University of Warwick Coventry University Chairman of Trustees South Asian Health Foundation Hon Chair Warwick UK
Primary Care Diabetes & Vascular Medicine Diabetes Research Centre and The Centre for Black Minority Health University of Leicester, Trustee, South Asian Health Foundation Leicester UK

Research output: Contribution to journal › Review article › peer-review

16 Citations (Scopus)

13 Downloads (Pure)

Abstract

South Asians constitute approximately 1.6 billion people from the Indian subcontinent, comprising Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Pakistan and Sri Lanka; and make up the largest diaspora globally. Compared to the White European population, this group is at a higher risk of developing type 2 diabetes along with cardiovascular, renal and eye complications. Over the recent years, a number of new therapies for type 2 diabetes have become available for which cardiovascular outcome trials (CVOTs) have been published. The recent ADA/EASD consensus guidelines on diabetes, pre-diabetes and cardiovascular diseases’ offer a transitional shift in type 2 diabetes management. The new consensus recommendations are based on recent CVOTs, many of which had a representation of South Asian cohorts. In light of this new evidence, there is urgent need for an integrated, evidence-based, cost-effective and individualised approach specific for South Asians. This review takes into consideration the evidence from these CVOTs and provides best practice recommendations for optimal management of South Asian people with type 2 diabetes, alongside the previously published consensus report from South Asian Health Foundation in 2014 [1].

Original language	English
Article number	e14497
Journal	Diabetic medicine
Volume	38
Issue number	4
Early online date	10 Dec 2020
DOIs	https://doi.org/10.1111/dme.14497
Publication status	Published - Apr 2021

Bibliographical note

This is the peer reviewed version of the following article: Hanif, W., Ali, S., Bellary, S., Patel, V., Farooqi, A., Karamat, M.A., Saeed, M., Sivaprasad, S., Patel, K. and Khunti, K. (2020), Pharmacological management of South Asians with Type 2 Diabetes: Consensus Recommendations from the South Asian Health Foundation. Diabetic Medicine. Accepted Author Manuscript e14497., which has been published in final form at https://doi.org/10.1111/dme.14497. This article may be used for non-commercial purposes in accordance With Wiley Terms and Conditions for self-archiving.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

South Asians
cardiovascular disease
cardiovascular outcome trials
glucagon-like peptide-1 receptor agonists
practice guidelines
sodium-glucose transporter 2 inhibitors
type 2 diabetes

Access to Document

10.1111/dme.14497Licence: CC BY-NC 3.0

Pharmacological management of South Asians with Type 2 Diabetes
This is the peer reviewed version of the following article: Hanif, W., Ali, S., Bellary, S., Patel, V., Farooqi, A., Karamat, M.A., Saeed, M., Sivaprasad, S., Patel, K. and Khunti, K. (2020), Pharmacological management of South Asians with Type 2 Diabetes: Consensus Recommendations from the South Asian Health Foundation. Diabetic Medicine. Accepted Author Manuscript e14497., which has been published in final form at https://doi.org/10.1111/dme.14497. This article may be used for non-commercial purposes in accordance With Wiley Terms and Conditions for self-archiving.
Accepted author manuscript, 15.6 MB

Cite this

@article{5c30ad69ea44491aa24a180edebd0408,

title = "Pharmacological management of South Asians with type 2 diabetes: Consensus recommendations from the South Asian Health Foundation",

abstract = "South Asians constitute approximately 1.6 billion people from the Indian subcontinent, comprising Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Pakistan and Sri Lanka; and make up the largest diaspora globally. Compared to the White European population, this group is at a higher risk of developing type 2 diabetes along with cardiovascular, renal and eye complications. Over the recent years, a number of new therapies for type 2 diabetes have become available for which cardiovascular outcome trials (CVOTs) have been published. The recent ADA/EASD consensus guidelines on diabetes, pre-diabetes and cardiovascular diseases{\textquoteright} offer a transitional shift in type 2 diabetes management. The new consensus recommendations are based on recent CVOTs, many of which had a representation of South Asian cohorts. In light of this new evidence, there is urgent need for an integrated, evidence-based, cost-effective and individualised approach specific for South Asians. This review takes into consideration the evidence from these CVOTs and provides best practice recommendations for optimal management of South Asian people with type 2 diabetes, alongside the previously published consensus report from South Asian Health Foundation in 2014 [1].",

keywords = "South Asians, cardiovascular disease, cardiovascular outcome trials, glucagon-like peptide-1 receptor agonists, practice guidelines, sodium-glucose transporter 2 inhibitors, type 2 diabetes",

author = "Wasim Hanif and Sarah Ali and Srikanth Bellary and Vinod Patel and Azhar Farooqi and Karamat, \{Muhammad Ali\} and Mujahid Saeed and Sobha Sivaprasad and Kiran Patel and Kamlesh Khunti",

note = "This is the peer reviewed version of the following article: Hanif, W., Ali, S., Bellary, S., Patel, V., Farooqi, A., Karamat, M.A., Saeed, M., Sivaprasad, S., Patel, K. and Khunti, K. (2020), Pharmacological management of South Asians with Type 2 Diabetes: Consensus Recommendations from the South Asian Health Foundation. Diabetic Medicine. Accepted Author Manuscript e14497., which has been published in final form at https://doi.org/10.1111/dme.14497. This article may be used for non-commercial purposes in accordance With Wiley Terms and Conditions for self-archiving.",

year = "2021",

month = apr,

doi = "10.1111/dme.14497",

language = "English",

volume = "38",

journal = "Diabetic medicine",

issn = "0742-3071",

publisher = "Wiley-Blackwell",

number = "4",

}

TY - JOUR

T1 - Pharmacological management of South Asians with type 2 diabetes

T2 - Consensus recommendations from the South Asian Health Foundation

AU - Hanif, Wasim

AU - Ali, Sarah

AU - Bellary, Srikanth

AU - Patel, Vinod

AU - Farooqi, Azhar

AU - Karamat, Muhammad Ali

AU - Saeed, Mujahid

AU - Sivaprasad, Sobha

AU - Patel, Kiran

AU - Khunti, Kamlesh

N1 - This is the peer reviewed version of the following article: Hanif, W., Ali, S., Bellary, S., Patel, V., Farooqi, A., Karamat, M.A., Saeed, M., Sivaprasad, S., Patel, K. and Khunti, K. (2020), Pharmacological management of South Asians with Type 2 Diabetes: Consensus Recommendations from the South Asian Health Foundation. Diabetic Medicine. Accepted Author Manuscript e14497., which has been published in final form at https://doi.org/10.1111/dme.14497. This article may be used for non-commercial purposes in accordance With Wiley Terms and Conditions for self-archiving.

PY - 2021/4

Y1 - 2021/4

N2 - South Asians constitute approximately 1.6 billion people from the Indian subcontinent, comprising Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Pakistan and Sri Lanka; and make up the largest diaspora globally. Compared to the White European population, this group is at a higher risk of developing type 2 diabetes along with cardiovascular, renal and eye complications. Over the recent years, a number of new therapies for type 2 diabetes have become available for which cardiovascular outcome trials (CVOTs) have been published. The recent ADA/EASD consensus guidelines on diabetes, pre-diabetes and cardiovascular diseases’ offer a transitional shift in type 2 diabetes management. The new consensus recommendations are based on recent CVOTs, many of which had a representation of South Asian cohorts. In light of this new evidence, there is urgent need for an integrated, evidence-based, cost-effective and individualised approach specific for South Asians. This review takes into consideration the evidence from these CVOTs and provides best practice recommendations for optimal management of South Asian people with type 2 diabetes, alongside the previously published consensus report from South Asian Health Foundation in 2014 [1].

AB - South Asians constitute approximately 1.6 billion people from the Indian subcontinent, comprising Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Pakistan and Sri Lanka; and make up the largest diaspora globally. Compared to the White European population, this group is at a higher risk of developing type 2 diabetes along with cardiovascular, renal and eye complications. Over the recent years, a number of new therapies for type 2 diabetes have become available for which cardiovascular outcome trials (CVOTs) have been published. The recent ADA/EASD consensus guidelines on diabetes, pre-diabetes and cardiovascular diseases’ offer a transitional shift in type 2 diabetes management. The new consensus recommendations are based on recent CVOTs, many of which had a representation of South Asian cohorts. In light of this new evidence, there is urgent need for an integrated, evidence-based, cost-effective and individualised approach specific for South Asians. This review takes into consideration the evidence from these CVOTs and provides best practice recommendations for optimal management of South Asian people with type 2 diabetes, alongside the previously published consensus report from South Asian Health Foundation in 2014 [1].

KW - South Asians

KW - cardiovascular disease

KW - cardiovascular outcome trials

KW - glucagon-like peptide-1 receptor agonists

KW - practice guidelines

KW - sodium-glucose transporter 2 inhibitors

KW - type 2 diabetes

UR - https://onlinelibrary.wiley.com/doi/epdf/10.1111/dme.14497

UR - https://www.scopus.com/pages/publications/85101011094

U2 - 10.1111/dme.14497

DO - 10.1111/dme.14497

M3 - Review article

C2 - 33301625

SN - 0742-3071

VL - 38

JO - Diabetic medicine

JF - Diabetic medicine

IS - 4

M1 - e14497

ER -

Pharmacological management of South Asians with type 2 diabetes: Consensus recommendations from the South Asian Health Foundation

Abstract

Bibliographical note

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this